Trial Profile
A Phase 1 Proof-of-Concept Study Investigating AZD6738 Monotherapy and Acalabrutinib in Combination With AZD6738 (ATR Inhibitor) in Subjects With Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Ceralasertib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Proof of concept
- Sponsors Acerta Pharma
- 24 Jan 2024 Planned End Date changed from 30 Jun 2023 to 28 Jun 2024.
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
- 01 Mar 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.